Survival Outcomes of the Intention-to-Treat, Weighted Intention-to-Treat, and Per-Protocol Populations
cancer, tumor
CANCER, TUMOR, LYMPH NODE METASTASIS
CRTCT indicates simultaneous integrated boost radiotherapy with concurrent and consolidated oral S-1 chemotherapy; HR, hazard ratio; RT, simultaneous integrated boost radiotherapy alone.Subgroup analyses showed that different baseline characteristics (age, sex, ECOG PS, CCI, nutrition status, dietary status, tobacco or alcohol consumption status) or cancer status (tumor length, location or lymph node metastasis status) were associated with different outcomes with CRTCT in terms of OS, except for patients with T1-2 lesion (